While we are thrilled to share a recent press release from Modalis Therapuetics , it’s important to keep in mind that the information provided includes “forward‑looking statements.” That means the company is sharing what they hope or plan to do, but these steps are not guaranteed and can change. The scientific paper mentioned in the press release describes years of careful testing of Modalis’ experimental therapy for LAMA2 (called MDL‑101) in animal models. Publishing this w

In honor of Mother’s Day 2025, Cure CMD asked five incredible mothers to reflect on caregiving, resilience, and the unexpected joys of...

CMD Community Member, Ashley Burkman, has written a new book, “Move,” featuring characters living with congenital muscular dystrophy.

We are honored to support groundbreaking discoveries related to LAMA2-Related Dystrophy.

Long-awaited publication about the Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related Dystrophy now published.